ArticleFrontiers in immunology2021
Optimizing a Multi-Component Intranasal
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- ID93 + GLA-3M-052-LS vaccine candidate administered by heterologous routes improves BCG efficacy against TB.Frontiers in immunology · 2026Article
- The ID93 + GLA-3M-052-LS vaccine candidate elicits mucosal and systemic immunogenicity and protective efficacy againstbioRxiv : the preprint server for biology · 2025Article
- Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant.NPJ vaccines · 2025Article
- Immunogenicity and safety of anHuman vaccines & immunotherapeutics · 2024Article
- Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.Frontiers in immunology · 2024Article
- Choice of adjuvant and antigen composition alters the immunogenic profile of a SARS-CoV-2 subunit vaccine.Frontiers in drug delivery · 2024Article
- Practical Considerations for Next-Generation Adjuvant Development and Translation.Pharmaceutics · 2023Review
- Small molecule metabolites: discovery of biomarkers and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions.NPJ vaccines · 2023Article
- Review
- Intranasal delivery of a synthetic Entamoeba histolytica vaccine containing adjuvant (LecA + GLA-3 M-052 liposomes): In vitro characterization.International journal of pharmaceutics · 2022Article
- Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection.Science translational medicine · 2022Article
- Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.NPJ vaccines · 2021Article
- The State of Art of Extracellular Traps in Protozoan Infections (Review).Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 1 country.
Mayuresh M AbhyankarDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
Mark T OrrInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Robert KinseyInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Sandra SivananthanInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Andrew J NafzigerDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
David N OaklandDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
Mary K YoungDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
Laura FarrDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
Md Jashim UddinDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
Jhansi L LeslieDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
Stacey L BurgessDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
Hong LiangInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Ines De LimaInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Elise LarsonInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Jeffrey A GuderianInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Susan LinInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Aaron KahnInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Prakash GhoshInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Sierra ReedInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Mark A Tomai3M Corporate Research Materials Laboratory, 3M Center, St Paul, MN, United States.
Karl PedersenTECHLAB, Inc., Blacksburg, VA, United States.
William A PetriDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States.
Christopher B FoxInfectious Disease Research Institute (IDRI), Seattle, WA, United States.
Infectious Disease Research Institute · USUniversity of Virginia Health System · USTechLab (United States) · USUniversity of Washington · US
Funding
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2MGut microbiome communication with the bone marrow regulates intestinal inflammation.R01AI146257 · NIAID · UNIVERSITY OF VIRGINIA · PI BURGESS, STACEY L · 2020 to 2025
$2.0MNIAID NIH HHS HHSN272201800025CNIAID NIH HHS R01 AI146257NIAID NIH HHS T32 AI007496
Abstract
Amebiasis is a neglected tropical disease caused by
Indexed as
Adjuvants, ImmunologicAdministration, IntranasalAnimalsAntibodies, ProtozoanAntigens, ProtozoanChemical PhenomenaCytokinesDrug CompoundingEntamoeba histolyticaEntamoebiasisEnzyme-Linked Immunosorbent AssayHumansImmunogenicity, VaccineImmunoglobulin GLiposomesMiceAdjuvants, ImmunologicAntibodies, ProtozoanAntigens, ProtozoanCytokinesImmunoglobulin GLiposomesProtozoan Vaccinesdesign of experimentsEntamoeba histolyticaformulationintranasalliposomeTLR ligandvaccine adjuvant
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.